Table 2.
Clinical and Imaging Differences Between Intermediate AMD Patients Remaining Stable and Progressing to Either Complete RPE and Outer Retinal Atrophy or Wet AMD
| Intermediate AMD to cRORA | Stable Intermediate AMD | Intermediate AMD to Wet AMD | |
|---|---|---|---|
| Eyes | 19 (37.3%) | 21 (41.2%) | 11 (21.6%) |
| Age, years | 74.7 ± 5.8 | 68.9 ± 6.3 | 75.6 ± 5.1 |
| AREDS2 supplement | 14 (73.7%) | 18 (85.7%) | 8 (72.7%) |
| F/U length | 37.8 ± 10.0 | 38.1 ± 8.0 | 41.6 ± 8.3 |
| Baseline VA, ETDRS letters | 75.9 ± 9.9 | 80.6 ± 6.2 | 77.5 ± 7.2 |
| Baseline iHRF | 19 (100%) | 19 (90.5%) | 10 (90.9%) |
| Baseline SDD | 10 (52.6%) | 3 (14.3%) | 5 (45.5%) |
| Baseline hDC | 8 (42.1%) | 0 (0%) | 2 (18.2%) |
| Baseline SCT, µm (SD) | 208 (96) | 254 (108) | 215 (61) |
| Baseline DV3, mm3 | 0.12 ± 0.16 | 0.14 ± 0.20 | 0.18 ± 0.14 |
| Baseline IC-FD – 3 mm, % | 17.7 ± 2.9 | 16.1 ± 2.6 | 18.2 ± 3.1 |
| Baseline IC-FD – 6 mm, % | 18.0 ± 4.1 | 16.4 ± 2.5 | 17.1 ± 3.0 |
cRORA, complete RPE and outer retinal atrophy; DV3, drusen volume in the central 3 mm; ETDRS, Early Treatment for Diabetic Retinopathy study; F/U, follow-up; iAMD, intermediate AMD; SCT, subfoveal choroidal thickness; SDD, subretinal drusenoid deposits; VA, visual acuity.